Combinational Treatments of RNA Interference and Extracellular Vesicles in the Spinocerebellar Ataxia

Overview

Journal Front Mol Neurosci

Specialty Molecular Biology

Date 2022 Oct 31

PMID 36311034

Authors

Yingying Ding

Yong Zhang

Xuehong Liu

Affiliations

Soon will be listed here.

Abstract

Spinocerebellar ataxia (SCA) is an autosomal dominant neurodegenerative disease (ND) with a high mortality rate. Symptomatic treatment is the only clinically adopted treatment. However, it has poor effect and serious complications. Traditional diagnostic methods [such as magnetic resonance imaging (MRI)] have drawbacks. Presently, the superiority of RNA interference (RNAi) and extracellular vesicles (EVs) in improving SCA has attracted extensive attention. Both can serve as the potential biomarkers for the diagnosing and monitoring disease progression. Herein, we analyzed the basis and prospect of therapies for SCA. Meanwhile, we elaborated the development and application of miRNAs, siRNAs, shRNAs, and EVs in the diagnosis and treatment of SCA. We propose the combination of RNAi and EVs to avoid the adverse factors of their respective treatment and maximize the benefits of treatment through the technology of EVs loaded with RNA. Obviously, the combinational therapy of RNAi and EVs may more accurately diagnose and cure SCA.

Citing Articles

Delivery of SAV-siRNA via Exosomes from Adipose-Derived Stem Cells for the Treatment of Myocardial Infarction.

Bai W, Zhu T, Zuo J, Li Y, Huang X, Li G Tissue Eng Regen Med. 2023; 20(7):1063-1077.

PMID: 37801227 PMC: 10645647. DOI: 10.1007/s13770-023-00588-z.

References

Yap K, Azmin S, Che Hamzah J, Ahmad N, van de Warrenburg B, Mohamed Ibrahim N . Pharmacological and non-pharmacological management of spinocerebellar ataxia: A systematic review. J Neurol. 2021; 269(5):2315-2337. DOI: 10.1007/s00415-021-10874-2. View

Hirunagi T, Sahashi K, Tachikawa K, Leu A, Nguyen M, Mukthavaram R . Selective suppression of polyglutamine-expanded protein by lipid nanoparticle-delivered siRNA targeting CAG expansions in the mouse CNS. Mol Ther Nucleic Acids. 2021; 24:1-10. PMC: 7937577. DOI: 10.1016/j.omtn.2021.02.007. View

Kara G, Calin G, Ozpolat B . RNAi-based therapeutics and tumor targeted delivery in cancer. Adv Drug Deliv Rev. 2022; 182:114113. DOI: 10.1016/j.addr.2022.114113. View

Harrell C, Volarevic V, Djonov V, Volarevic A . Therapeutic Potential of Exosomes Derived from Adipose Tissue-Sourced Mesenchymal Stem Cells in the Treatment of Neural and Retinal Diseases. Int J Mol Sci. 2022; 23(9). PMC: 9105552. DOI: 10.3390/ijms23094487. View

Mishra N, Ashique S, Garg A, Rai V, Dua K, Goyal A . Role of siRNA-based nanocarriers for the treatment of neurodegenerative diseases. Drug Discov Today. 2022; 27(5):1431-1440. DOI: 10.1016/j.drudis.2022.01.003. View

Bonafede R, Brandi J, Manfredi M, Scambi I, Schiaffino L, Merigo F . The Anti-Apoptotic Effect of ASC-Exosomes in an In Vitro ALS Model and Their Proteomic Analysis. Cells. 2019; 8(9). PMC: 6770878. DOI: 10.3390/cells8091087. View

Mori M, Ludwig R, Garcia-Martin R, Brandao B, Kahn C . Extracellular miRNAs: From Biomarkers to Mediators of Physiology and Disease. Cell Metab. 2019; 30(4):656-673. PMC: 6774861. DOI: 10.1016/j.cmet.2019.07.011. View

Longoni B, Fasciani I, Kolachalam S, Pietrantoni I, Marampon F, Petragnano F . Neurotoxic and Neuroprotective Role of Exosomes in Parkinson's Disease. Curr Pharm Des. 2019; 25(42):4510-4522. DOI: 10.2174/1381612825666191113103537. View

Wang W, Zhou P, Wang X, Chen F, Christensen E, Thompson J . Efficient and Precise Processing of the Optimized Primary Artificial MicroRNA in a Huntingtin-Lowering Adeno-Associated Viral Gene Therapy and in Mice and Nonhuman Primates. Hum Gene Ther. 2021; 33(1-2):37-60. PMC: 10112875. DOI: 10.1089/hum.2021.221. View

10.

Borgonio-Cuadra V, Valdez-Vargas C, Romero-Cordoba S, Hidalgo-Miranda A, Tapia-Guerrero Y, Cerecedo-Zapata C . Wide Profiling of Circulating MicroRNAs in Spinocerebellar Ataxia Type 7. Mol Neurobiol. 2019; 56(9):6106-6120. DOI: 10.1007/s12035-019-1480-y. View

11.

Loch-Neckel G, Matos A, Vaz A, Brites D . Challenges in the Development of Drug Delivery Systems Based on Small Extracellular Vesicles for Therapy of Brain Diseases. Front Pharmacol. 2022; 13:839790. PMC: 9002061. DOI: 10.3389/fphar.2022.839790. View

12.

Sandau U, McFarland T, Smith S, Galasko D, Quinn J, Saugstad J . Differential Effects of APOE Genotype on MicroRNA Cargo of Cerebrospinal Fluid Extracellular Vesicles in Females With Alzheimer's Disease Compared to Males. Front Cell Dev Biol. 2022; 10:864022. PMC: 9092217. DOI: 10.3389/fcell.2022.864022. View

13.

Roshani F, Delavar Kasmaee H, Falahati K, Arabzade G, Sohan Forooshan Moghadam A, Sanati M . Analysis of Micro-RNA-144 Expression Profile in Patients with Multiple Sclerosis in Comparison with Healthy Individuals. Rep Biochem Mol Biol. 2022; 10(3):396-401. PMC: 8718777. DOI: 10.52547/rbmb.10.3.396. View

14.

Nonaka W, Takata T, Iwama H, Komatsubara S, Kobara H, Kamada M . A cerebrospinal fluid microRNA analysis: Progressive supranuclear palsy. Mol Med Rep. 2022; 25(3). PMC: 8809115. DOI: 10.3892/mmr.2022.12604. View

15.

Athauda D, Gulyani S, Karnati H, Li Y, Tweedie D, Mustapic M . Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients With Parkinson Disease: A Secondary Analysis of the Exenatide-PD Trial. JAMA Neurol. 2019; 76(4):420-429. PMC: 6459135. DOI: 10.1001/jamaneurol.2018.4304. View

16.

Joshi B, Youssef S, Bron R, de Bruin A, Kampinga H, Zuhorn I . DNAJB6b-enriched small extracellular vesicles decrease polyglutamine aggregation in and models of Huntington disease. iScience. 2021; 24(11):103282. PMC: 8564107. DOI: 10.1016/j.isci.2021.103282. View

17.

Zhang Q, Higginbotham J, Jeppesen D, Yang Y, Li W, McKinley E . Transfer of Functional Cargo in Exomeres. Cell Rep. 2019; 27(3):940-954.e6. PMC: 6559347. DOI: 10.1016/j.celrep.2019.01.009. View

18.

Cui F, Xu Z, Lv Y, Hu J . Role of spindle pole body component 25 in neurodegeneration. Ann Transl Med. 2021; 9(18):1432. PMC: 8506722. DOI: 10.21037/atm-21-4064. View

19.

Jalles A, Vieira C, Pereira-Sousa J, Vilasboas-Campos D, Mota A, Vasconcelos S . Aripiprazole Offsets Mutant ATXN3-Induced Motor Dysfunction by Targeting Dopamine D and Serotonin 1A and 2A Receptors in . Biomedicines. 2022; 10(2). PMC: 8962381. DOI: 10.3390/biomedicines10020370. View

20.

Bonafede R, Turano E, Scambi I, Busato A, Bontempi P, Virla F . ASC-Exosomes Ameliorate the Disease Progression in SOD1(G93A) Murine Model Underlining Their Potential Therapeutic Use in Human ALS. Int J Mol Sci. 2020; 21(10). PMC: 7279464. DOI: 10.3390/ijms21103651. View